Moleculin Biotech, Inc. (Nasdaq: MBRX) announced interim efficacy results from the first 45 patients enrolled in Part A of its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE